Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Update on ATLAS: Overall survival

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

We learned several months ago that the ATLAS trial of maintenance Avastin (bevacizumab) with either Tarceva (erlotinib) or placebo did not demonstrate a significant improvement in overall survival (OS) with Tarceva, despite the fact that it was associated with an improvement in progression-free survival (PFS). This is in contrast with the similar trial called SATURN that randomized advanced NSCLC patients after first line chemo to maintenance Tarceva vs. placebo, but without the Avastin during and after first line chemo, as SATURN demonstrated a significant improvement in OS along with a significant improvement in PFS. In Dr. Mark Socinski's great overview of the topic of maintenance therapy, he noted these discrepant results, with no obvious explanation. We received additional information about the OS results at ASCO, where it was reported that at the latest time point of analysis, in July of 2009, the median OS was 15.9 months vs. 13.9 months, favoring the addition of Tarceva. This corresponded with a hazard ratio of 0.90, or 10% improvement, over the entire course of treatment, a result that was not statistically significant. The overall survival curves are shown below: atlas-os-curves-kabbinavar-asco-2010 (click on image to enlarge) Admittedly, it doesn't look like a major separation, but there is a modest advantage with the combination. You can decide whether that's a glass half empty or half full.

My take on these results is that the trend was still favorable, even if the trend was non-significant, so they don't really challenge the conclusions of the SATURN trial. This is similar to what we might say about the Fidias trial and maintenance chemotherapy, which demonstrated a greater than 2 month difference in OS that wasn't statistically significant, so the trial was called "negative", but we've seen positive trials that showed less impressive improvements in absolute terms. In addition, the ATLAS trial was stopped early, after it met its primary endpoint of improvement in PFS. One final thing I find intriguing about the ATLAS trial is that certain subgroups of patients receiving the combination of Tarceva and Avastin appeared to have a particular benefit. Namely, Asian/Pacific Islander patients and never-smokers (both groups that we know have a higher incidence of an EGFR mutation) and those specifically tested and found to have an EGFR mutation (less than half of the enrolled patients had tissue available for molecular testing for an EGFR mutation) had a very notable improvement in OS). This is shown as the circles being to the left of the vertical line on the right side of the figure below for those groups. atlas-os-by-clinical-subsets While this is just a retrospective assessment of relatively small subsets, these same groups were the ones who demonstrated a particularly strong OS benefit in the related BeTa trial, which compared Tarceva alone to Tarceva with Avastin as second line treatment for patients who hadn't received prior Avastin. So these findings suggest that the Tarceva/Avastin combination may truly be particularly effective, even compared with Tarceva alone, in patients who have the molecular and clinical features associated with the greatest benefit from an EGFR mutation. Apparently I'm not the only person who has come to this conclusion, because the CALGB, one of the major US-based cooperative oncology research groups, is now planning a trial comparing Tarceva/Avastin to Tarceva alone as first line therapy for patients with an identified EGFR mutation. It will take a few years, but can expect to learn more about this question in the next few years.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on